Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis.
OBJECTIVE
To report two cases in which a bull's eye maculopathy developed after intravitreal injection of fomivirsen.


METHODS
Case reports.


RESULTS
A 50-year-old man with acquired immunodeficiency syndrome (AIDS) and refractory cytomegalovirus retinitis developed bull's-eye pigmentary changes in the macula of the right eye after initiating therapy with fomivirsen (Vitravene; CIBA Vision, Atlanta, Georgia) intravitreal injections. These pigmentary changes resolved upon cessation of treatment. A 36-year-old man with AIDS and refractory bilateral cytomegalovirus retinitis developed bull's-eye pigmentary changes in both eyes during bilateral intravitreal treatment with fomivirsen. Vision was not affected. These changes resolved after treatment with fomivirsen was stopped.


CONCLUSIONS
Fomivirsen, a new medication for the treatment of refractory cytomegalovirus retinitis, may cause a bull's-eye maculopathy in some patients. The bull's-eye maculopathy is reversible and does not appear to affect vision.
Stone
T W
TW
Duke University Eye Center, Durham, North Carolina 27710, USA.
Jaffe
G J
GJ
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008266:Macula Lutea / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced* / Q000503:physiopathology; D013873:Thionucleotides / Q000009:adverse effects* / Q000627:therapeutic use; D014792:Visual Acuity; D014822:Vitreous Body
D000998:Antiviral Agents; D013873:Thionucleotides; C091346:fomivirsen